Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye. In the U.S., Aerie markets Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor, and the fixed-dose combination Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Rhokiinsa® (netarsudil 200 micrograms/ml eye drops solution) has received marketing authorization in the EU. Aerie has development operations in Europe and Japan and a global manufacturing facility in Ireland. The company’s ophthalmic pipeline includes three clinical-stage programs in dry eye and retina.